Fierce Medtech names Owkin a 'Fierce 15' Med Tech Company of 2021
Owkin today announced that it has been named by Fierce Medtech as one of 2021’s Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.
Owkin is a startup that uses artificial intelligence to find the right treatment for every patient. Founded in 2016, Owkin uses AI and federated learning to identify new drug candidates, de-risk and accelerate clinical trials and build diagnostic tools that improve patient outcomes. In November 2021, Owkin became a unicorn through a $180 million investment from biopharma company Sanofi.
Thomas Clozel MD, Co-founder and CEO of Owkin, said:
“We are honored to be recognised by Fierce as one of the most promising, innovative and creative med tech companies in the world. This is a testament to the dedication of my team and our academic, clinical and biopharma partners, who work tirelessly to bring the latest innovations in AI and biology to patients.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is Fierce Medtech’s 10th annual Fierce 15 selection. This year’s full list of winners can be viewed online.
“While we’re not fully out of the woods yet when it comes to COVID-19, the innovations pursued by this year’s class of 15 companies will help the industry evolve, either in step with the pandemic or in spite of it,” said Conor Hale, senior editor of Fierce Medtech.
An internationally recognized daily report reaching a network of over 90,000 med tech industry professionals, Fierce Medtech provides subscribers with an authoritative analysis of the day's top stories. Every year Fierce Medtech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
About Fierce Medtech
Fierce Medtech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology. More than 90,000 top industry professionals rely on Fierce Medtech for an insider briefing on the day's top stories.
About Owkin
Owkin is the first end-to-end AI biotech company on a mission to understand complex biology and ensure every patient gets the right treatment.
We identify precision therapeutics, de-risk and accelerate clinical trials, and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular disease, and immunity and inflammation.
Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across nine cancer indications.
Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.
